

INDEX

Note: Page numbers in *italics* indicate figures.
Page numbers followed by a “t” indicate tables.

- Abbreviations, 510-515
ACAM2000 (smallpox vaccine), 431, 431t, 433-435
 CPT and ICD-9-CM codes, 127t
Acetaminophen, 117
ACIP. See *Advisory Committee on Immunization Practices*.
ActHIB (Hib-T), 289, 290t-292t
 CPT and ICD-9-CM codes, 125t
 efficacy/immunogenicity, 289
 recommendations, 289-293
Active Bacterial Core surveillance, 64
Active immunization, 11-16
Acute disseminated encephalomyelitis (ADEM), 358
Acute illness, as precaution, 156. See also *specific vaccines*.
Acute otitis media (AOM), 440, 442
Ad-hoc committees and task forces, 68-69
Adacel (Tdap), 252, 272t-275t. See also *Tdap vaccine*.
 CPT and ICD-9-CM codes, 128t
Adaptive immune system, 17-21
Additives in vaccines, 213-214, 489
Adenocarcinomas, HPV and, 319
Adenovirus vaccine, 15
Adenylate cyclase toxin, 267
Adjuvants, 27. See also *specific vaccines*.
 aluminum salts, 212-213
 AS04, 213, 324t
 interactions of, 489
 safety concerns, 212-213
Administration of vaccines, 113-117. See also *Delivery of vaccines*.
 anxiety, pain, and fever, dealing with, 117
 CPT codes for, 130t-133t
 emergencies following, 117-122
 errors in, and remedies, 149, 152t-154t
 general rules for, 139-155
 intervals between vaccines, 139-141, 142t-146t
 live vaccines and antibody-containing products, 148-149, 150t-151t
 intramuscular, 116, 118, 120t-121t
 intranasal, 116-117
 multiple vaccines, simultaneous administration of, 70t, 113-116, 139
 oral, 115
 preferred sites and needle length, 120t-121t
 schedules for, 241-256
 subcutaneous, 116, 118, 120t-121t
Adolescent immunization
 coverage, 62, 91
 hepatitis B vaccine, 242, 312
 HPV vaccine, 255
 mandates for, 102
Adolescent immunization (*continued*)
 schedules
 catch-up, 248t
 routine, 245t
 syncope and, 119
 Tdap vaccine for, 271
 waning immunity and, 209
Adolescents, sexual activity among, 321
Adoptees, international, 178-179
Adult immunization
 financing of, 78-79
 mandates/legislation on, 102-103
 schedules. See also *specific vaccines*.
 by age group, 249t
 by medical condition, 250t-251t
 standards for, 91, 92t
Adverse events, 43, 191-192. See also *Vaccine Safety Net; specific vaccines*.
 emergencies following vaccine administration, 117-122
 package insert information, 55-56
 Reportable Events Table, 94t-95t
 reporting system (VAERS), 66-67, 96
Advertising claims, package insert and, 56
Advisory Commission on Childhood Vaccines, 93-96, 505
Advisory Committee on Immunization Practices (ACIP), 56-58, 57, 497, 505
 recommendations, 55, 58-59
 working groups, 58
Advocacy organizations, 506-507
Aedes aegypti mosquitoes, 473-474, 478
Afluria (IIV, influenza), 340t-342t
 CPT and ICD-9-CM codes, 125t-126t
Age. See also *Schedules for immunizations*.
 adult immunization schedule by, 249t
 grace period for immunizations, 103
 minimum ages for routine vaccines, 141, 142t-146t
Agenticity, 194-195
Agriflu (IIV, influenza), 340t-342t
AIDS, polio vaccine and, concerns about, 234-235. See also *HIV*.
Alastrim (variola minor), 426
Alcoholism, vaccination recommendations, 250t-251t
All Kids Count, 506
Allergies. See also *specific vaccines*.
 concern about vaccines causing, 215-217
 delayed-type hypersensitivity, 155
 to eggs, 338, 351, 352
 to gelatin, 214
 severe, to vaccine/components, 155, 213-214
Allied Vaccine Group, 506
Aluminum salts, 212-213
American Academy of Family Physicians (AAFP), 506
American Academy of Pediatrics (AAP), 506
 Red Book, iv, 59

- American College Health Association (ACHA), 506
 American Immunization Registry Association, 111
 American Nurses Association (ANA), 506
 American Pharmacists Association (APA), 506
 American Public Health Association (APHA), 506
 Anal cancers, 320
 Anamnestic response, 26
 Anaphylaxis/anaphylactic shock, 94t, 119-122
 symptoms, 119
 treatment, 119-122
 Anesthetics, topical, 117
 Animal viruses, natural attenuation for humans, 14
 Animal workers, vaccination of, 188t
 Anogenital warts, 320
 Anthrax, 257-265, 516t
 antibiotic therapy for, 259
 as bioterrorism agent, 258
 clinical features, 257
 cutaneous, gastrointestinal, inhalational, and oropharyngeal
 anthrax, 257
 epidemiology and transmission, 257-258
 immunization program, 258-259
 pathogen, 257
 vaccines for, 259, 260t
 civilian use, 258-259, 264t-265t
 contraindications/precautions, 147, 261-262
 CPT and ICD-9-CM codes, 124t
 efficacy/immunogenicity, 259
 military use, 259, 262
 pre-exposure vaccination, 259
 recommendations/schedule, 260t, 262, 264t-265t
 safety, 261-262
 storage, 260t
 Antibodies, 21-30. See also *Immune globulin*.
 action mechanisms and sites, 21
 engineered, 17
 germline, 23
 inactivation of live vaccines by, 148
 measurement of, 37-39
 passive immunization with, 16-17
 persistence of, 29-30
 production of, 21-30
 extrafollicular reaction, 22-23, 22
 germinal center reaction, 23-30, 25
 specificity of, 28-29
 testing for, 149
 time course of responses, 28
 Antibody-containing blood products
 intervals for live vaccines and, 148-149, 150t-151t
 recent receipt of, as precaution, 467
 Antibody-dependent cell-mediated cytotoxicity, 21
 Antigen-presenting cells (APCs), 24-26, 25
 Antigen-sparing, 27
 Antigens, 21. See also *Antibodies*.
 antigenic competition, 489
 antigenic drift/antigenic shift, 333
 number of, in routine vaccines, 211t
 reassortment, 333
 T-cell independent, 23
 Antihistamine, 122
 Antitoxins, in passive immunization, 17
 Antivaccinationism, 200-204, 201t-203t, 205t-207t
 Anxiety, dealing with, 117
 AOM. See *Acute otitis media*.
 APCs. See *Antigen-presenting cells*.
 Apoptosis, 34
 Arthritis, Hib and, 287
 Arthus-type reaction, 280, 281
 AS04, 213, 324t
 Aspirin use, 188t, 354, 467
 Reye syndrome and, 462, 467
 Asplenia, 164-165, 440
 vaccination recommendations, 250t-251t, 388, 451t
 Association for Prevention Teaching and Research (APTR), 506
 Association for Professionals in Infection Control
 and Epidemiology, 102
 Asthma
 as contraindication, 353-354
 as indication for PPSV23, 253
 pneumonia risk and, 450
 vaccine concerns and, 216
 Attenuation of vaccines, 11-15
 engineered, 14-15
 heterologous host, 14
 route of inoculation, 15
 serial passage, 11-14
 Autism, 219-229
 MMR vaccine and, 70t, 219-222, 221, 223, 225-226
 Omnibus Autism Proceedings, 225-226
 safety review findings, 71t
 thimerosal and, 224-229, 227, 228
 Autoimmune disease, vaccines and, 215-217
 Avian flu. See *Bird flu*.
 B cells, 21-23, 22, 25
 memory, 25, 26, 29
 Bacille Calmette-Guérin (BCG), 14
Bacillus anthracis, 257. See also *Anthrax*.
 Bacteremia, 287, 439, 454, 462
 Bacteria. See also *specific bacteria*.
 attenuation of, 14
 lysis/opsonization of, 21
 vaccines against, 34
 BCG. See *Bacille Calmette-Guérin*.
 Behavioral Risk Factor Surveillance System (BRFSS), 62, 63, 507
 Billing. See *Coding and billing*.

Biohazard labels, 101

Biologics License Application (BLA), 54

Bioterrorism

- anthrax and, 257, 258, 262
- polio and, 353
- smallpox and, 44, 426

BioThrax, 124t, 260t, 261

Bird flu (influenza A; H5N1), 334, 335, 336

- vaccine for, 339

BLA (Biologics License Application), 54

Bleeding diathesis, 188t

Blood products, intervals for live vaccines and, 148-149, 150t-151t

Blood transfusion, interval for live vaccines and, 150t

Bloodborne Pathogens Standard, 97-102

Bone marrow transplantation. *See Hematopoietic stem cell transplantation.*

Books on vaccines, iv, 508-509

Booster vaccination, 27-28, 28

Boostrix (Tdap), 252, 272t-275t. *See also Tdap vaccine.*

- CPT and ICD-9-CM codes, 128t

Bordetella pertussis, 15, 267, 269. *See also Pertussis.*

Brain damage, pertussis vaccine concerns, 229-231

Breast-feeding, 175, 421. *See also Pregnancy.*

- as contraindication, 264t, 436, 477

BRFSS. *See Behavioral Risk Factor Surveillance System.*

Brighton Collaboration, 67-68, 507

Buccal cellulitis, 287

Buffers, 155, 489

Butte County, California, HepA in, 301

Cancer

- chemotherapy for, 165-167
- HPV and, 319-320
- vaccines and, 70t, 234

Carrier-induced epitopic suppression, 489-490

Catch-up immunization schedules

- children, age 4 months-6 years, 246t-247t
- children, age 7-18 years, 248t

CBER. *See Centers for Biologics Evaluation and Research.*

CDC. *See Centers for Disease Control and Prevention.*

Cell-mediated immunity defects, 163

Cellulitis, Hib and, 287

Centers for Biologics Evaluation and Research (CBER), 49-51, 50, 505

Centers for Disease Control and Prevention (CDC), 505

- monitoring and surveillance, 64
- vaccine policy and, 56, 57

Centers for Medicare & Medicaid Services (CMS), 505

Cervarix (HPV2), 27, 324t-326t. *See also Human papillomavirus.*

- efficacy/immunogenicity, 323-327
- recommendations, 329-330
- safety, 329
- schedule, 125t, 255, 325t

Cervical cancer, 255, 319-320, 321

Cervical intraepithelial neoplasia (CIA) grades, 320

Cervical transformation zone, 319

Chemotherapy

- impaired immunity and, 165-167
- pneumonia vaccination and, 450

Chickenpox. *See Varicella.*

Childhood Immunization Support Program, 59

Children. *See also Infants.*

- anxiety and pain, dealing with, 117
- cocoon strategy, 110
- costs of immunization, 72-73, 72t, 88-89
- coverage rates, 60-63, 61, 111
- CPT codes, 130t-131t
- HIV-exposed/infected, vaccination issues, 167-169
- immunization schedules

 - catch-up, age 4 months-6 years, 246t-247t
 - catch-up, age 7-18 years, 248t
 - combination vaccines in, 255-256

- exemptions, 103
- financing for, 73, 74-78
- grace period for, 103
- hepatitis A, 297, 302
- hepatitis B, 312
- pneumonia, 447, 448t
- routine, age 0-6 years, 243t-244t
- routine, age 7-18 years, 245t
- school mandates and state legislation, 102-103
- travel and, 182
- routine health care recommendations, 91
- Vaccines for Children (VFC) Program, 74-78

Children's Hospital of Philadelphia Vaccine Education Center, 507

Children's Vaccine Program at PATH, 507

Chronic disease, impaired immunity and, 165

Chronic liver disease, vaccination recommendations, 250t-251t, 302, 313, 354

Chronic lung disease, vaccination recommendations, 250t-251t

Chronic meningococemia, 379-380

Cidofovir, 436

CISA. *See Clinical Immunization Safety Assessment (CISA) Network.*

Civic duty, immunization as, 198

Classification of vaccines, 12t-13t

Clinical Immunization Safety Assessment (CISA) Network, 67, 507

Clinical trials, 51-54, 51

- numbers of subjects required, 51, 52, 53t

Clinically preventable burden, 47

Clonal expansion, 22

Clostridium tetani, 267, 269. *See also Tetanus.*

Clotting-factor disorders, 302

CoCASA (Comprehensive Clinic Assessment Software Application), 113, 507

Cochlear implants

- pneumonia risk and, 448
- pneumonia vaccination and, 450
- vaccination and, 188t

- Cocoon strategy, 110
- Coding and billing, 122-136
 - CPT (Current Procedural Terminology) codes, 122-134
 - immune globulin administration, 128t-129t
 - preventive medicine services, 122, 123t
 - vaccine administration, 122, 130t-133t
 - vaccines and immune globulins, 122, 124t-129t
 - ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes, 122-134
 - preventive medicine services, 123t
 - vaccines and immune globulins, 124t-129t
 - National Drug Codes (NDCs), 134
 - routine office visit, example, 134, 135t
- College students, vaccination of, 188t, 355, 388
- Combination vaccines, 489-504, 517t
 - advantages of, 489, 490-491, 497, 503t
 - background on, 489
 - barriers to adoption of, 491
 - contraindications/precautions, 497
 - development, evaluation, and licensure of, 489-490
 - disadvantages of, 497, 503t
 - DTap-based, 242, 492t-496t
 - efficacy/immunogenicity, 491
 - incorporating in pediatric schedule, 244t, 255-256
 - noninferiority standard, 490
 - other, 498t-502t
 - overimmunization and, 497
 - preference for, 497
 - production of, 489-490
 - quality, effect on, 490-491
 - recommendations on, 497
 - safety, 491-497
 - schedule, 497
- Communicating about vaccines, 191-240. See also *Concerns about vaccines, addressing*.
 - communicating risks and benefits, 191-197, 208-236
 - specific concerns and questions, 208-236
 - strategies for, 195-197
 - tips for, 195-196
 - vaccine refusal, 197-200
- Complement assays, 383-387
- Complement deficiencies, 159-160, 163-164
 - vaccination recommendations, 250t-251t, 388
- Complement-mediated lysis, 21
- Component vaccines, 12t-13t, 15-16. See also *specific combination vaccines*.
- Comprehensive Clinic Assessment Software Application (CoCASA), 113, 507
- Comvax (HepB-Hib-OMP), 242, 252, 498t-502t
 - component vaccines/composition, 498t
 - CPT and ICD-9-CM codes, 125t
 - schedule, 500t-501t
- Concerns about vaccines, addressing, 191-240
 - antivaccinationism, 200-204, 201t-203t
 - flawed thinking, 205t
 - public harm from, 206t-207t
 - communicating risks and benefits, 191-197
 - communication strategies, 195-197
 - probabilistic and heuristic thinking, 192-195
 - costs of public concern, 204-208, 206t-207t
 - specific concerns, 208-236
 - additives, safety of, 213-214
 - adjuvants, danger of, 212-213
 - AIDS, polio vaccine and, 234-235
 - allergies and autoimmune disease causation, 215-217
 - alternative schedules, 214-215
 - autism, MMR vaccine and, 219-222, 221, 223
 - autism, thimerosal and, 224-229, 227, 228
 - brain damage, pertussis vaccine and, 229-231
 - cancer, vaccines and, 234
 - fetal tissue in vaccine manufacture, 217-219
 - Guillain-Barré syndrome, vaccines and, 231-232
 - Kawasaki disease, vaccines and, 236
 - mad cow disease, vaccines and, 233-234
 - multiple sclerosis, vaccines and, 232
 - multiple vaccines, immune overload and, 70t, 210-212, 211t
 - natural infection vs immunization, 209-210
 - necessity for vaccines, 208-209
 - SIDS, vaccines and, 235
 - vaccine refusal, 197-200
 - Condyloma acuminata, HPV and, 320
 - Confidentiality, protecting, 111-112
 - Confirmation bias, 194
 - Contaminants, 213-214. See also *specific vaccines*.
 - Contraindications and precautions, 155-156. See also *specific vaccines*.
 - distinguishing, 156
 - erroneous contraindications, 156, 157t-158t
 - impaired immunity and, 250t, 255
 - screening for, 113, 114t-115t
 - Correctional facility staff/inmates, vaccination of, 189t, 297, 302, 313, 355
 - Correlates of protection, 36-39, 38t
 - Corynebacterium diphtheriae*, 267, 269. See also *Diphtheria*.
 - Costs, 72-79
 - cost-benefit analysis, 47
 - influenza vaccination, 338
 - N meningitidis* vaccination, 381-382
 - pneumococcal vaccination, 441
 - rotavirus vaccination, 415
 - varicella vaccination, 464
 - zoster (shingles) vaccination, 483-484
 - financing methods, 72-79
 - provider costs for vaccination services, 136t
 - of public concern about vaccines, 204-208
 - public/private sector participation in, 72-79, 73

Costs (*continued*)
of registry maintenance, 112
of routine childhood vaccinations, 72t
of vaccine development, 49
of vaccines (purchase price), 134-136. See also *specific vaccines*.
Coverage, 60-64, 109-111
Coverage and assessment groups, 507-508
Cowpox, 14. See also *Smallpox*.
Cows, mad cow disease and, 233-234
CPT (Current Procedural Terminology) codes, 122-134
for immune globulin administration, 132t
pediatric-specific, 130t-131t
for preventive medicine services, 123t
for routine office visit at 6 months, 135t
for vaccine administration, 130t-133t
for vaccines and immune globulins, 124t-129t
Creutzfeldt-Jakob disease, variant (vCJD), 233-234
Criteria for immunity, 374t-375t
-CRM suffix, 517t (footnote)
Cross-protection, 29, 35
Culex mosquitoes, 358
Current Procedural Terminology codes. See *CPT codes*.
Cytokines, 24, 33, 33
Cytomegalovirus immune globulin intravenous (CMV-IGIV), 150t
Cytotoxic T cells (Tc cells), 30-35, 33, 305
implications for vaccination, 34-35
Th1-cells and, 26, 33, 33
Cytotoxicity, antibody-dependent cell-mediated, 21
Cytotoxins, 34

Danish Cohort Study
Hib vaccine and diabetes, 217, 218
MMR and autism, 222, 223
thimerosal and autism, 226-229, 228

Daptacel (DTaP), 272t-275t
CPT and ICD-9-CM codes, 124t
efficacy, 279

Day care center staff, vaccination of, 189t, 355

Decavac (Td, preservative-free), 276t-278t
CPT and ICD-9-CM codes, 127t

Delayed-type hypersensitivity, 155

Delivery of vaccines
improving, 108-113
expanding access, 109-110
Immunization Information Systems (IISs), 111-112
missed opportunities, 109
other strategies, 112-113
reminder, recall, and tracking systems, 108-109
standing orders, 110-111
monitoring, 60-64

Dendritic cells, 24-26, 25

Department of Defense (DOD), 505

Department of Health and Human Services, 56, 57, 505-506

Development. See *Vaccine development and licensure*.
Developmentally disabled, vaccination of staff for, 189t, 313

Diabetes, 217, 218
vaccination recommendations, 250t-251t

DiGeorge syndrome, 155-156, 160, 163

Diphenhydramine, 122

Diphtheria, 267-286, 516t. See also *Pertussis*; *Tetanus*.
clinical features, 268
epidemiology and transmission, 269
immunization program, 270
infection vs disease, 269
morbidity and mortality from, 46t
pathogen, 267
toxoid, 276t-278t
vaccines for, 272t-278t. See also *DT*; *DTaP vaccine*; *Tdap vaccine*.
adult. See *Tdap vaccine*.
children/infants. See *DTaP vaccine*.
combination vaccines, 492t-496t
contraindications/precautions, 279-281
CPT and ICD-9-CM codes, 124t
efficacy/immunogenicity, 271-279
indications, 273t, 277t
recommendations, 281-283
safety, 279-281
schedule, 274t, 277t
storage, 274t, 277t

Diphtheria and Tetanus Toxoids Adsorbed USP (for Pediatric Use; DT), 276t-278t

Disease-modifying antirheumatic drugs (DMARDs), 167

Diseases. See also *specific diseases*.
chronic, 165
vaccinating patients who have already had, 147-148
vaccination goals for, 44-45
vaccine-preventable, monitoring, 64-65

Do no harm, 193

Doses of vaccine
administration errors, and remedies, 152t-154t
multidose series, administration of, 141
partial or fractional, 141

Dryvax (smallpox vaccine), 430, 433-434
CPT and ICD-9-CM codes, 127t

DT (diphtheria, tetanus toxoids), 276t-278t
contraindications/precautions, 280-281
recommendations, 281

DTaP vaccine, 272t-275t. See also *Daptacel*; *Infanrix*; *Tripedia*.
combination vaccines, 242, 492t-496t
component vaccines/composition, 492t-493t
safety, 491
schedule, 244t, 495t
contraindications/precautions, 279-280
coverage, 61, 61
CPT and ICD-9-CM codes, 124t, 130t
efficacy/immunogenicity, 279

- DTaP vaccine (*continued*)
 recommendations, 281
 safety, 279-280
 schedule, 242, 274t
 administration errors, and remedies, 152t-153t
 catch-up, children age 4 months-6 years, 246t
 children, age 0-6 years, 243t, 244t
 minimum ages and intervals, 140-141, 142t
 shortages of, 84
 vs Tdap, 147
 DTwP vaccine, 489
- Eczema, as contraindication for vaccination, 435
 Education on immunizations, 112-113
 Effectiveness, monitoring, 64-65
 Efficacy
 correlates of protection, 36-39, 38t
 efficacy/immunogenicity. *See specific vaccines.*
- Eggs, allergy to, 338, 351, 352
 Elimination of disease, 44-45
 Embryonic cells, use in vaccine production, 217-219
 Emergencies following vaccine administration, 117-122
 anaphylaxis, 119-122
 preparation for, 117-119
 standing orders for, 119
 syncope, 119
 Emergencies, vaccine storage and handling during, 107t
 Emerging Infections Program Network (CDC), 64
 EMLA cream, 117
 Encephalitis
 Japanese, 357-364
 postvaccination (yellow fever vaccine), 476, 478
 Encephalopathy
 acute, as vaccine contraindication, 155, 280
 concerns about, 204
 End stage renal disease (ESRD), vaccination recommendations, 250t-251t, 313
 Engerix-B (HepB), 241-242, 308t-310t
 CPT and ICD-9-CM codes, 125t
 dosing, 309t, 312
 efficacy/immunogenicity, 311
 schedule, 309t
 Engineered agent vaccines, 12t-13t
 Engineered attenuation, 14-15
 Engineered subunits, 16
Epidemiology and Prevention of Vaccine-Preventable Diseases.
 See "Pink Book".
- Epiglottitis, 287
 Epilepsy, as vaccination contraindication/precaution, 280
 Epitopes, 21
 epitope spreading, 27
 epitopic suppression, carrier-induced, 489-490
 Eradication of disease, 44-45
 Erythema, 279, 434, 484
 Every Child by Two (ECBT), 507
 Excipients and contaminants, 155, 213-214. *See also specific vaccines.*
 interactions of, 489
 Exemptions from school immunization requirements, 103
 Exposure-control plan, 97-100
 Extinction of disease, 44-45
 Extrafollicular reaction, 22-23, 22
- FDA. *See Food and Drug Administration (FDA).*
 Fear of vaccines, harm from, 204-208, 206t-207t
 Febrile multiple organ-system failure, 476
 Febrile seizures, 191, 369, 491-497
 Federal requirements regarding vaccination, 98t-99t
 Fetal tissue in vaccine manufacture, 217-219
 Fever, dealing with, 117
 Filamentous hemagglutinin (FHA), 267, 272t, 493t
 Fimbriae (FIM), 267, 272t, 493t
 Financing of immunization, 72-79, 73
 adults, 78-79
 children, 74-78
 cost of vaccines, 72-73, 72t
 future of, 79
 NVAC recommendations, 80t-81t
 public/private sector participation, 72-79, 73
 Flu. *See Influenza.*
 Fluarix (IIV, influenza), 340t-342t
 CPT and ICD-9-CM codes, 125t-126t
 Flulaval (IIV, influenza), 125t, 340t-342t
 Flumist (LAIV, live influenza), 127t, 254, 343t-346t
 Fluvirin (IIV, influenza), 343t-346t
 CPT and ICD-9-CM codes, 125t-126t
 Fluzone (IIV, influenza), 343t-346t
 CPT and ICD-9-CM codes, 125t-126t
 Fluzone-High Dose (IIV, influenza), 343t-346t, 351
 Folk numeracy, 194
 Food and Drug Administration (FDA), 49, 57, 505
 Food handlers, vaccination of, 188t, 303-304
 Foresters, vaccination of, 188t
 Formaldehyde, 213-214
 Freeloading, 193-194
 Freezers, 105-106, 107t
FUTURE (Females United To Unilaterally Reduce Endo/Ectocervical Disease) I and II, 322-323
- GABHS (group A beta-hemolytic streptococcus), 462
 GamaSTAN S/D (immune globulin, human, IM), 128t
 Gardasil (HPV4), 255, 324t-326t. *See also Human papillomavirus.*
 CPT and ICD-9-CM codes, 125t
 efficacy/immunogenicity, 322-323
 recommendations, 329-330
 safety, 328-329
 Gastroenteritis. *See Rotavirus.*

Gelatin, 214, 233. See also *specific vaccines*.

Genetics of vaccine responses and adverse events, 43

Genital warts, 319, 329-330

Germinal center reaction, 23-30, 25
implications for vaccination, 26-30

Germline antibodies, 23

Global Alliance for Vaccines and Immunization (GAVI), 507

Gloves, 100-101, 116
not routinely needed, 149

Good Clinical Practices (GCPs), 51

Good Laboratory Practices (GLPs), 49

Good Manufacturing Practices (GMPs), 49, 52

Governmental agencies and committees, 56-60, 57, 505-506

Grace period, 103, 140-141

Group A beta-hemolytic streptococcus (GABHS), 462

Guillain-Barré syndrome, 68, 231-232
as contraindication/precaution
for diphtheria/tetanus/pertussis vaccines, 280, 281
for influenza vaccines, 351, 352, 353
for MCV4, 156, 388

Gulf War Syndrome, 261

H1N1 influenza, 68, 231
vaccine, 181, 231
administration, 131t, 139
mandates and, 102

Haemophilus influenzae type b (Hib), 287-293, 516t. See also *Influenza*.
clinical features, 287
diabetes and, 217, 218
epidemiology and transmission, 287-288
herd immunity and, 40, 288
immunization program, 288
morbidity and mortality from, 46t
newborn protection against, 16
pathogen, 287
vaccines for, 288, 290t-292t
combination vaccines, 252-253, 492t-496t, 498t-502t
contraindications/precautions, 289
correlates of protection, 37, 38t
coverage, 61, 61
CPT and ICD-9-CM codes, 124t, 125t, 130t
efficacy/immunogenicity, 288-289
minimum ages and intervals, 142t
recommendations, 289-293
safety, 95t, 289
schedule, 252-253, 291t
administration errors, and remedies, 153t
catch-up, children age 4 months-6 years, 246t
children, age 0-6 years, 243t
combination vaccines, 244t
shortages of, 84

Handling, storage, and transport of vaccines, 105-108

Harm, from fear of vaccines, 204-208, 206t-207t

Harmless, definition of, 191

HAV. See *Hepatitis A*.

Havrix (HepA), 255, 298t-300t
CPT and ICD-9-CM codes, 124t
efficacy/immunogenicity, 297-301

HBIG. See *Hepatitis B immune globulin (HBIG)*.

HCP. See *Health care personnel*.

HDVC. See *Imovax Rabies*.

Health care personnel, 179-181
needlestick injuries/blood exposure, 97-102
vaccination recommendations, 101, 102, 180-181, 250t-251t, 313, 355, 427, 437
contraindications/precautions, 353

Healthcare Effectiveness Data and Information Set (HEDIS), 507

Healthy People 2010, 87, 111
vaccine coverage goals, 62, 63

Healthy People 2020, 87

Heart disease, vaccination recommendations, 250t-251t

HEDIS. See *Healthcare Effectiveness Data and Information Set*.

Helper T lymphocytes (Th cells), 24-26, 25

Hemagglutinin, 340t, 343t

Hematopoietic stem cell transplantation (HSCT), 169, 170t-172t

Hemodialysis, vaccination recommendations, 250t-251t

HepaGam B (hepatitis B immune globulin), 307
CPT and ICD-9-CM codes, 128t

Hepatitis A, 295-304
in Butte County, California, 301
clinical features, 295
disease vs infection, 296
epidemiology and transmission, 295-296
endemic regions of world, 185t-187t
herd immunity and, 40-43, 41
immunization program, 46, 296-297
morbidity and mortality from, 46t
pathogen, 295
vaccines for, 297, 298t-300t
combination vaccines, 498t-502t
contraindications/precautions, 301
CPT and ICD-9-CM codes, 124t-125t
efficacy/immunogenicity, 297-301
minimum ages and intervals, 142t
preferred over immune globulin, 302-303
recommendations, 255, 297, 302-304
postexposure prophylaxis, 297, 302-304
pre-exposure prophylaxis, 297, 302
for travel, 183, 297, 302
universal childhood immunization, 46, 302
safety, 95t, 301
schedule, 255, 299t
adults, by age, 249t
adults, by medical condition/indication, 250t
catch-up, children age 4 months-6 years, 247t
catch-up, children age 7-18 years, 248t

- Hepatitis A, schedule (*continued*)
 children, age 0-6 years, 243t
 children, age 7-18 years, 245t
 shortages of, 84
- Hepatitis B, 305-318
 chronic carriers, 305
 clinical features, 305-306
 epidemiology and transmission, 306
 HBsAg/HBsAb status and, 242, 306-308, 316t-318t
 testing for, 313-314
 immunization program, 306-307
 incidence, 307
 morbidity and mortality from, 46t
 pathogen, 305
 vaccines for, 15, 307-311, 308t-310t. See also *Hepatitis B immune globulin*.
 combination, 242, 244t, 492t-496t, 498t-502t
 contraindications/precautions, 312
 correlates of protection, 37, 38t
 coverage, 61-62, 61
 CPT and ICD-9-CM codes, 125t
 efficacy/immunogenicity, 311
 minimum ages and intervals, 142t
 recommendations, 312-315
 adult vaccination, 312-314
 during pregnancy, 306-307
 for health care personnel, 101, 102, 180, 313
 for nonoccupational exposures, 318t
 for occupational exposures, 316t-317t
 postexposure prophylaxis, 314-315, 316t-318t
 preterm and low birth weight infants, 175
 for travel, 183
 universal infant, child and adolescent immunization, 312
 reportable events, 95t
 safety, 70t, 311-312
 MS concern, 232, 310-311
 SIDS concern, 235
 schedule, 241-242, 309t
 administration errors, and remedies, 153t
 adults, by age, 249t
 adults, by medical condition/indication, 251t
 birth dose, 241-242, 312
 deferral of, 312
 catch-up, children age 4 months-6 years, 246t
 catch-up, children age 7-18 years, 248t
 children, age 0-6 years, 243t
 children, age 7-18 years, 245t
 standing orders for, 312, 313
 waning immunity and, 311
- Hepatitis B immune globulin (HBIG), 307
 contraindications, 307-311
 interval for receipt of live vaccines, 151t
 recommendations
 for exposed neonates, 314-315
- Hepatitis B immune globulin (HBIG), recommendations (*continued*)
 for nonoccupational exposures, 318t
 for occupational exposures, 316t-317t
 safety, 307-311
- Hepatitis B surface antigen/antibody. See *Hepatitis B, HBsAg/HBsAb status*.
- Herd immunity, 39-43, 41-42
 threshold, 40
- Herpes zoster (shingles). See *Zoster (herpes zoster; shingles)*.
- Heterologous host, 14
- Heterologous hyperimmune sera, 17
- Heterologous infections, 212
- Heterotypic responses, 29
- Heuristic thinking about vaccines, 192-195
- Hib. See *Haemophilus influenzae type b*.
- Hib-OMP. See *PedvaxHIB*.
- Hib-T. See *ActHIB*.
- Hiberix (HibT), 252, 289, 290t-292t
 efficacy/immunogenicity, 289
 recommendations, 289-293
- HIV (human immunodeficiency virus) infection, 167-169
 in children/adolescents, MMR vaccination and, 376
 immunoprophylaxis and, 162
 live vaccines and, 160
 pneumonia and, 440, 450
 polio vaccine, concerns, 234-235
 universal precautions, 101-102
 vaccination recommendations, 250t-251t, 313-314, 354, 376, 389, 451t, 468
 contraindications/precautions, 477
- Home visits for vaccination, 110
- Homotypic responses, 29
- Hooper, Edward, 234
- Household contacts, immunization of, 160-161, 161t, 313, 355, 376, 459, 468
 contraindications/precautions, 353
- HPV. See *Human papillomavirus (HPV)*.
- HPV2. See *Human papillomavirus (HPV)*, vaccines for.
- HPV4. See *Human papillomavirus (HPV)*, vaccines for.
- HRV. See *Rotavirus, vaccines for; human (HRV)*.
- HSCT. See *Hematopoietic stem cell transplantation*.
- Human complement assay, 383-387
- Human embryo cell lines, 217-219
- Human immunodeficiency virus. See *HIV*.
- Human leukocyte antigens (HLAs), 24, 43
- Human papillomavirus (HPV), 319-331, 516t
 clinical features, 319-320
 epidemiology and transmission, 320-321
 immunization program, 321-322
 pathogen, 319
 vaccines for, 322, 324t-326t
 contraindications/precautions, 329
 cross-protection from, 323

- Human papillomavirus (HPV), vaccines for (*continued*)
 efficacy/immunogenicity, 322-327
 HPV2 (Cervarix), 27, 324t-326t
 CPT and ICD-9-CM codes, 125t
 efficacy/immunogenicity, 323-327
 HPV4 (Gardasil), 322-323, 324t-326t
 CPT and ICD-9-CM codes, 125t
 efficacy/immunogenicity, 322-323
 immunization program, 321-322
 schedule, 255, 325t
 adults, by age, 249t
 adults, by medical condition/indication, 250t
 catch-up, children age 7-18 years, 248t
 females age 7-18 years, 245t
 minimum ages and intervals, 142t-143t
 recommendations, 255, 329-330
 safety, 95t, 328-329
- Human rabies immune globulin (HRIG). See *Rabies immune globulin, human*.
- Human rotavirus vaccine. See *Rotavirus, vaccines for, human (HRV)*.
- Humoral immune deficiencies, 159, 163
- Hundred-day cough, 268. See also *Pertussis*.
- Hydroxyzine, 122
- Hygiene hypothesis, 215-216
- HyperHEP B S/D (hepatitis B immune globulin, human), 128t, 307
- Hyperimmune globulins, in passive immunization, 16-17
- HyperRAB S/D (rabies immune globulin), 128t, 400
- Hypersensitivity, delayed-type, 155
- HyperTET (tetanus immune globulin), 129t
- Hyporesponsiveness, 23
- ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes, 122, 134
 for preventive medicine services, 123t
 routine office visit, example, 135t
 for vaccines and immune globulins, 124t-129t
- ICD-10-CM, compliance date, 134
- IgA deficiency, selective, 401
- IGIM (intramuscular immune globulin), 17, 150t
- IGIV (immune globulin, intravenous), 17, 150t, 169
- Illegal drug users, vaccination of, 188t, 302, 303, 306, 313
- Immigrants, vaccination policies on, 178-179
- Immune deficiency. See *Impaired immunity*.
- Immune globulin, 16-17. See also *Antibodies; specific immune globulins*.
 administration procedure, 116
 CPT and ICD-9-CM codes, 128t-129t, 132t
 intervals for vaccination with live vaccines, 149, 150t-151t
 intramuscular (IGIM), 17, 150t
 intravenous (IGIV), 17, 150t, 169
 isotypes, 21
 vaccination preferred over, 302-303
- Immune memory, 26, 29
- Immune overload, concerns about, 210-212, 211t, 214
- Immune response, 17-35
 adaptive immune system, 17-21
 anamnestic response, 26
 antibodies, 21-30
 persistence of, 29-30
 antigens, 21
 cytotoxic T cells, 30-35
 extrafollicular reaction, 22-23, 22
 germinal center reaction, 23-30, 25
 homotypic vs heterotypic, 29
 hygiene hypothesis, 215-216
 innate immune system, 23-24
 stimulating, 26-27
 multiple immunizations and, 70t, 210-212, 211t
 priming and boosting, 27-28
- Immune thrombocytopenic purpura, 371
- Immunity
 criteria for (specific diseases), 374t-375t
 impaired. See *Impaired immunity*.
 surrogates of, 36-39, 38t
 testing for, 149
 waning, 209
- Immunization, 11-17
 active, 11-16
 booster, 27-28
 correlates of protection, 36-39
 definition of, 11
 education on, 112-113
 herd immunity, 39-43, 41-42
 mandates and legislation regarding, 102-103
 passive, 16-17
 primary, 27-28, 28
 reactions to. See *Adverse events*.
 schedules. See *Schedules for immunizations*.
 screening for, 113, 114t-115t
 standards. See *Standards, principles, and regulations*.
- Immunization Action Coalition (IAC), 113, 507
- Immunization Information Systems (IISs), 111-112
- Immunization programs. See also *specific vaccines*.
 impact of, 45-47, 46t, 191
- Immunization Safety Review Committee (ISRC), 69, 70t-71t
- Immunocompromised states. See *Impaired immunity*.
- Immunogenicity, 30, 31, 36. See also *specific vaccines*.
- Immunogenicity bridging studies, 52
- Immunoglobulins, transfer in pregnancy, 16
- Immunosuppression, 165-167, 212. See also *Impaired immunity*.
- Imogam Rabies-HT (rabies immune globulin), 128t, 400
- Imovax Rabies (RAB-HDC), 402t-404t
 CPT and ICD-9-CM codes, 127t
 safety, 400-401
- Impact of vaccines/vaccination programs, 45-47, 46t, 191

- Impaired immunity, 159-173
 - close contacts, immunization of, 160-161, 161t
 - general considerations, 159-162
 - HIV infection, 167-169
 - live vaccines, contraindications/precautions for, 160, 435
 - medication-induced immunosuppression, 165-167
 - official recommendations vs product labeling, 161-162
 - passive immunoprophylaxis, 162
 - pneumonia risk and, 450
 - risk-benefit balance of vaccination, 159
 - specific states other than HIV infection, 162-165
 - vaccine contraindications/precautions, 250t, 255, 371, 401, 421, 435, 477, 484
 - vaccine recommendations, 250t-251t, 255, 313-314, 354, 450
- Inactivated vaccines, 12t-13t, 15
 - characteristics of, 18t-20t
 - intervals for vaccination, 140
 - vs live vaccines, 18t-20t, 35
- Infanrix (DTaP), 272t-275t
 - CPT and ICD-9-CM codes, 124t
 - efficacy, 279
- Infants. See also *Children*.
 - hepatitis B vaccination, 175, 241-242, 314-315
 - HIV-exposed/infected, 167-168
 - pneumonia vaccination, 447, 448t
 - preterm and low birth weight, 175
 - rotavirus vaccination, 242, 421-422
 - smallpox vaccination, precautions, 436
 - varicella vaccination, 468
- Infection
 - control/elimination/eradication/extinction of agents, 44-45
 - preventing, 21, 34-35
- Infectious Diseases Society of America (IDSA), 88, 102, 506
- Influenza, 333-356, 516t
 - clinical features, 335
 - epidemics and pandemics, 333-334, 336-337
 - Spanish flu (1918), 333-334
 - epidemiology and transmission, 335-337
 - immunization program, 337-338
 - mortality from, annual, 209, 336
 - pathogen, 333-334
 - strains, 333-337
 - A(H1N1), 333, 339
 - 2009, 68, 334
 - in 2010-2011 seasonal vaccine, 338
 - A(H3N2), 333, 334, 339, 350
 - A(H5N1), bird flu, 334, 335, 336
 - vaccine for, 339
 - B, 339
 - vaccines for, 338-339, 340t-346t, 516t
 - contraindications/precautions, 352-353
 - cost-benefit analysis, 338
 - coverage, 62, 63
- Influenza, vaccines for (*continued*)
 - CPT and ICD-9-CM codes, 125t-126t, 127t, 131t-132t
 - efficacy/immunogenicity, 339-347
 - egg protein allergy and, 213-214, 338, 339, 351, 352
 - Guillain-Barré syndrome and, 231, 351
 - health care workers, vaccination of, 102, 181, 353
 - IIV (inactivated), 340t-346t
 - contraindications/precautions, 351
 - differences from LAIV, 348t-349t
 - efficacy/immunogenicity, 347-350
 - high-dose, 343t-346t, 351
 - production of, 338
 - safety, 351
 - TIV (trivalent inactivated influenza virus vaccine), 346t
 - LAIV (live-attenuated), 343t-346t
 - attenuation of, 14-15
 - contraindications/precautions, 351-352, 353-354
 - CPT and ICD-9-CM codes, 127t, 131t-132t
 - differences from IIV, 348t-349t
 - efficacy/immunogenicity, 350
 - production of, 338-339
 - safety, 352-353
 - minimum ages and intervals, 143t
 - in pregnancy, 173
 - production of, 338-339
 - recommendations, 254, 337-338, 353-355
 - live vs inactivated vaccines, 348t-349t
 - priority groups, 254, 354-355
 - for travel, 183
 - universal immunization, 353-354
 - safety, 71t, 95t, 351-353
 - schedule, 255, 341t, 344t
 - administration errors, and remedies, 153t
 - adults, by age, 249t
 - adults, by medical condition or indication, 250t
 - children, age 0-6 years, 243t
 - children, age 7-18 years, 245t
 - shortages of, 84
 - swine flu, 68, 71t, 231
- Injection techniques and sites, 116, 118, 120t-121t
- Injury. See *National Childhood Vaccine Injury Act; Vaccine Injury Compensation Program*.
- Innate immune system, 23-24
- Innate immunity, stimulating, 26-27
- Institute for Vaccine Safety, Johns Hopkins Bloomberg School of Public Health, 507
- Institute of Medicine (IOM)
 - Immunization Safety Review Committee, 69, 70t-71t
 - report on vaccine financing, 80t-81t
- Intention-to-treat, 323
- International adoptees, refugees, and immigrants, 178-179
- International agencies, 506

- Intervals for vaccinations
 grace period, 140-141
 inactivated vaccines, 140
 live vaccines, 139-140
 between live vaccines and antibody-containing blood products,
 148-149, 150t-151t
 minimum acceptable, 140-141, 142t-146t
 simultaneous administration, 139
- Intramuscular (IM) administration of vaccines, 116, 118, 120t-121t
- Intramuscular (IM) immune globulin (IGIM), 17, 150t
- Intranasal administration of vaccines, 116-117
- Intravenous immune globulin (IGIV), 17, 150t, 169
- Intussusception, 415, 421
- Invasive pneumococcal disease (IPD), 439, 440. See also *Streptococcus pneumoniae*.
- IOM. See *Institute of Medicine*.
- IPOL (IPV), 253, 394t. See also *Polio, vaccines for*.
 CPT and ICD-9-CM codes, 126t
- IPV. See *Polio, vaccines for*.
- Isotype switching, 26
- ISRC. See *Immunization Safety Review Committee*.
- Ixiaro (JE-VC), 360t-361t
 CPT and ICD-9-CM codes, 126t
- Japanese encephalitis, 357-364, 516t
 clinical features, 357
 epidemiology and transmission, 357-358
 endemic regions of world, 185t-187t
 immunization program, 358-359
 pathogen (Japanese encephalitis virus; JEV), 357
 vaccines for, 359, 360t-361t
 contraindications/precautions, 362
 CPT and ICD-9-CM codes, 126t
 efficacy/immunogenicity, 359
 JE-MB, 358, 359, 360t-361t
 JE-VC, 358-359, 360t-361t
 recommendations, 363
 safety, 362
 schedule/storage, 361t
- JE-Vax (JE-MB), 126t, 360t-361t
- Jenner, Edward, 14, 44
- JEV (Japanese encephalitis virus). See *Japanese encephalitis*.
- Kawasaki disease, 55-56, 236
- Kidney failure, vaccination recommendations, 250t-251t, 354
- Kinrix (DTaP-IPV), 242, 254, 492t-496t
 component vaccines/composition, 492t-493t
 CPT and ICD-9-CM codes, 124t
 schedule, 495t
- Koplik's spots, 366
- Laboratory workers, vaccination of, 188t, 302, 363, 388, 427, 437, 458, 477-478
- LAIV (live-attenuated influenza vaccine), 343t-346t. See also *Influenza, vaccines for*; *LAIV (live-attenuated)*.
- Langerhans cells, 24
- Latex. See *specific vaccines*.
- Leukemia, impaired immunity and, 169
- Liability issues. See *National Childhood Vaccine Injury Act*; *National Vaccine Injury Compensation Program*.
- Licensure. See *Vaccine development and licensure*.
- Live-attenuated influenza vaccine. See *LAIV*.
- Live-attenuated vaccines, 12t-13t
- Live vaccines, 11, 12t-13t
 characteristics of, 18t-20t
 contraindications, 155, 160, 166
 impaired immunity and, 160, 166
 intervals for receipt of antibody-containing products, 148-149, 150t-151t
 intervals for vaccinations, 139-140
 live-attenuated, 12t-13t
 pregnancy and, 155, 174
 vs inactivated vaccines, 18t-20t, 35
- Liver disease, vaccination recommendations, 250t-251t, 302, 313, 354
- Local anesthetics, 117
- Lockjaw, 268
- Long-term care facilities, 189t, 355
- Low birth weight infants, 175
- Lung disease, vaccination recommendations, 250t-251t
- Lyssavirus*, 397. See also *Rabies*.
- Mad cow disease (MCD), vaccines and, 233-234
- Major histocompatibility complex (MHC)
 class I molecules (MHC-I), 30-33, 34
 class II molecules (MHC-II), 24, 31
 genes for, 43
- Mandates for vaccination, 102-103
- Manufacturers of vaccines, 508
 different, interchangeability of vaccines, 147
 number of, 82
- Marketing claims, package insert and, 56
- MCV4, 381, 384t-386t. See also *Neisseria meningitidis*.
 contraindications/precautions, 156, 388
 coverage, 62
 efficacy/immunogenicity, 382-387
 Guillain-Barré syndrome and, 231-232, 388
 licensure of, 39, 382, 383, 387
 MCV4-CRM, 382, 384t-386t, 388
 MCV4-D, 383-387, 384t-386t, 388
 recommendations, 255, 382, 388-389
 safety, 387-388
 schedule, 255, 385t
 administration errors, and remedies, 153t
 adults, by age, 249t
 adults, by medical condition/indication, 251t
 children, age 0-6 years, 243t

- MCV4, schedule (*continued*)
- children, age 7-18 years, 245t
 - minimum ages and intervals, 143t
 - shortages of, 84
 - vs MPSV, 147, 384t-386t
- Measles, Mumps, Rubella, 365-377, 516t
- clinical features, 366-367
 - criteria for immunity, 373, 374t-375t
 - epidemiology and transmission, 367-369
 - immunization program, 369
 - measles immune globulin, 376
 - measles outbreak in Indiana, 204-208
 - morbidity and mortality from, 46t, 209
 - pathogens, 365
 - vaccines for (MMR), 370, 372t-373t
 - combination. See *MMRV*.
 - contraindications/precautions, 371-373, 435-436
 - coverage, 61, 61
 - CPT and ICD-9-CM codes, 127t, 131t
 - efficacy/immunogenicity, 370-371
 - impact of vaccine refusal, 204-208
 - interval for receipt of antibody-containing products, 150t-151t
 - recommendations, 373-376
 - reportable events, 94t
 - safety, 217, 371-373
 - autism concerns, 219-222, 221, 223, 225-226
 - fear of MMR, public harm from, 204-208, 206t
 - thimerosal concerns, 208, 225-229
- schedule, 254, 372t
- adults, by age, 249t
 - adults, by medical condition/indication, 250t
 - catch-up, children age 4 months-6 years, 247t
 - catch-up, children age 7-18 years, 248t
 - children, age 0-6 years, 243t
 - children, age 7-18 years, 245t
 - minimum ages and intervals, 143t
 - vs MMRV, 369
- Medicaid, 63, 79, 80t, 505
- Medicare, 78, 505
- Medication-induced immunosuppression, 165-167
- Membrane attack complex, 21
- Membranous nasopharyngitis, 268
- Memory B-cells, 25, 26, 29
- Men who have sex with men, vaccination of, 188t, 302, 313
- Menactra (MCV4), 255, 384t-386t
- CPT and ICD-9-CM codes, 127t
- MenHibrix, CPT and ICD-9-CM codes, 125t
- Meningitis, 379-380. See also *Neisseria meningitidis*.
- bacterial, 439
 - Hib and, 288
- Meningococcal disease, vaccines for, 147. See also *Neisseria meningitidis*.
- Meningococcal polysaccharide conjugate vaccine, 4-valent. See *MPSV4*.
- Meningococemia*, 379
- Meningococemia, chronic, 379-380
- Meningococcus, endemic regions of world, 185t-187t
- Meningococcus. See *Neisseria meningitidis*.
- Menomune-A/C/Y/W-135 (MPSV4), 255, 384t-386t
- CPT and ICD-9-CM codes, 127t
- Menveo (MCV4-CRM), 255, 384t-386t
- CPT and ICD-9-CM codes, 127t
- Mercury in vaccines/thimerosal, 224
- MHC, MHC-I, MHC-II. See *Major histocompatibility complex*.
- Military personnel, vaccination of, 388
- anthrax vaccination, 259, 262
 - smallpox vaccination, 434-435
- Minimum acceptable intervals for vaccinations, 140-141, 142t-146t
- Minimum age for vaccination, 141, 142t-146t
- Misinformation, 200-204
- Missed opportunities, 109
- MMR vaccine. See *Measles, Mumps, Rubella, vaccines for*.
- MMRV vaccine, 254, 369
- combination vaccines, 498t-502t
 - contraindications/precautions, 373, 468, 497
 - interval for receipt of antibody-containing products, 150t-151t
 - in pediatric schedule, 244t
 - safety issues, 491-497
 - schedule/recommendations, 497
 - shortages of, 84
 - vs MMR, 369
- Monitoring
- for adverse events. See *Vaccine Adverse Event Reporting System*.
 - for vaccine delivery, 60-64
 - for vaccine effectiveness, 64-65
- Morbidity and mortality, from vaccine-preventable diseases, 46t
- Morbidity and Mortality Weekly Report*, 58-59
- Mortality, from vaccine-preventable diseases, 46t
- Morticians, vaccination of, 188t
- Mosquitoes
- Aedes aegypti*, yellow fever and, 473-474, 478
 - control/avoidance of, 474, 477
 - Culex*, Japanese encephalitis and, 358
- MPSV4 (meningococcal polysaccharide conjugate vaccine, 4-valent), 381, 384t-386t, 387. See also *Neisseria meningitidis*.
- CPT and ICD-9-CM codes, 127t
 - minimum ages and intervals, 143t
 - recommendations, 255
 - safety, 387
 - schedule
 - adults, by age, 249t
 - adults, by medical condition/indication, 251t
 - vs MCV, 147
- Multidose vaccine series, dosing intervals, 141
- Multiple sclerosis, vaccines and, 232, 310-311
- Multiple vaccines, simultaneous administration of, 70t, 113-116, 139
- immune overload concerns, 210-212, 211t
 - number of antigens, 211t

- Mumps, 365-377. See also *Measles, Mumps, Rubella*.
 clinical features, 366-367
 criteria for immunity, 373, 374t-375t
 epidemiology and transmission, 368
 immunization program, 369
 pathogen, 365
 resurgence of, 46, 46
 vaccines for, 370, 372t-373t
 contraindications/precautions, 371-373
 efficacy/immunogenicity, 370
 recommendations, 373-376
 safety, 371-373
- Mycobacterium bovis*, 14
- Nabi-HB (hepatitis B immune globulin), 307
 CPT and ICD-9-CM codes, 128t
- National Center for Immunization and Respiratory Diseases (NCIRD), 56, 505
- National Childhood Vaccine Injury Act, 66, 68, 91-97
- National Committee for Quality Assurance, 64
- National Drug Codes (NDCs), 134
- National Foundation for Infectious Diseases (NFID), 507
- National Health Interview Survey (NHIS), 62, 507
- National Immunization Survey (NIS), 60-62, 61, 508
- National Institutes of Health (NIH), 57, 505
- National Network for Immunization Information (NNii), 507
- National Notifiable Disease Surveillance System (NNDSS), 64, 508
- National Nursing Home Survey, 63
- National Respiratory and Enteric Surveillance System (NREVSS), 64-65
- National Vaccine Advisory Committee (NVAC), 60, 506
 financing recommendations, 80t-81t
 pediatric immunization standards, 88-91
- National Vaccine Injury Compensation Program (VICP), 90, 505
- National Vaccine Plan, 59-60
- National Vaccine Program Office (NVPO), 57, 59, 506
- Native Americans and Alaskans
 Hib infection and, 287, 288
 pneumonia and, 440
 vaccination of, 188t
- Natural infection, vs immunization, 209-210
- NCIRD. See *National Center for Immunization and Respiratory Diseases*.
- Necessity for vaccines, 208-209
- Necrotizing fasciitis, 212
- Needle length, 116, 118
- Needlestick injuries, 97-102
- Needlestick Safety and Prevention Act, 97
- Negri bodies, 397
- Neisseria meningitidis*, 379-390, 516t
 clinical features, 379-380
 epidemiology and transmission, 380
 immunization program, 381-382
 pathogen, 379
- Neisseria meningitidis* (continued)
 vaccines for, 382, 384t-386t, 516t. See also *MCV4; MPSV4*.
 contraindications/precautions, 388
 cost-benefit analysis, 381-382
 efficacy/immunogenicity, 382-387
 herd effects, 381
 MCV4-CRM, 382, 387
 MCV4-D, 383-387, 384t-386t
 MPSV4, 381, 384t-386t, 387
 recommendations, 388-389
 safety, 387-388
 schedule, 385t
- Neomycin, allergy to, 214
- Nephrotic syndrome, pneumonia vaccination in, 451t
- Neurotropic disease, vaccine-associated, 476
- Neutralization of viruses/toxins, 21
- New Vaccine Surveillance Network (NVSN), 64
- Nomenclature, 516t-517t
- Noninferiority, 52, 490
- NVAC. See *National Vaccine Advisory Committee*.
- NVPO. See *National Vaccine Program Office*.
- NVSN. See *New Vaccine Surveillance Network*.
- Observation period after vaccination, 117-119
- Obstructive laryngotracheitis, 268
- Occupational Safety and Health Administration (OSHA), 97-102
- Office visit
 coding for, example, 134, 135t
 communicating about vaccines in, 195-197
- Omnibus Autism Proceedings, 225-226
- OMP suffix, 517t (footnote)
- Opsonization, 21
- OPV. See *Polio, vaccines for*.
- Oral administration of vaccines, 116
- Original polysaccharide sin, 23
- Oropharyngeal cancers, 320
- OSHA. See *Occupational Safety and Health Administration*.
- Otitis media, 440, 442, 462
- Package insert (PI), 54-56
- Pain, dealing with, 117
- Palivizumab (RSV-mAb), 131t
- Pan American Health Organization (PAHO), 506
- Pap test, 320
- Parents of Kids With Infectious Diseases (PKID), 507
- PARSIFAL study, 217
- Partial doses, 141
- Passive immunization, 16-17
- Passive immunoprophylaxis, 162
- Pasteur, Louis, 14, 15
- Pathogen-specific molecular patterns, 24
- PATRICIA (Papilloma Trial Against Cancer In Young Adults), 3
- Patternicity, 194

- PCECV. See *RabAvert*.
- PCV7. See *Pneumococcal vaccines, PCV7*.
- PCV13. See *Pneumococcal vaccines, PCV13*.
- Pediarix (DTaP-HepB-IPV), 242, 253, 492t-496t
 component vaccines/composition, 492t-493t
 CPT and ICD-9-CM codes, 124t
 schedule, 495t
- Pediatric immunization practices. See also *Children*.
 CPT codes for, 130t-131t
 standards for, 88-91
- Pediatric Infectious Diseases Society (PIDS), 506
- PedvaxHIB (Hib-OMP), 252, 288-289, 290t-292t
 CPT and ICD-9-CM codes, 125t
 efficacy/immunogenicity, 288-289
 recommendations, 289-293
- Penile cancers, 320
- Pentacel (DTaP-IPV/Hib), 242, 252-253, 492t-496t
 component vaccines/composition, 492t-493t
 CPT and ICD-9-CM codes, 124t
- Pentavalent rotavirus vaccine (PRV). See *RotaTeq (rotavirus, RV5)*.
- Periorbital cellulitis, 287
- Permissive statements, 59
- Pertactin (PRN), 267, 272t, 493t
- Pertussis, 267-286, 516t
 catarrhal, paroxysmal, and convalescent stages, 268
 clinical features, 268-269
 epidemiology and transmission, 269-270
 immunity from natural infection, 281
 immunization program, 271
 incidence, 270
 morbidity and mortality from, 46t
 pathogen, 267
 resurgence of, 46t
 toxin (PT), 267
 vaccines for, 15, 272t-275t
 acellular, 271
 adult. See *Tdap vaccine*.
 children/infants. See *DTaP vaccine*.
 combination vaccines, 492t-496t
 contraindications/precautions, 279-281
 correlates of protection, 39
 efficacy/immunogenicity, 271-279
 encephalopathy and, 155, 204
 recommendations, 281-283
 safety, 94t, 279-281
 safety fears, 216
 brain damage, 229-231
 public cost of, 204, 206t
 schedule, 274t
 whole-cell, 271
 waning immunity and, 271
- Phagocyte disorders, 163
- Phase 1, 2, 3, and 4 trials, 51-54, 51
- Physical examination, no requirement for, 149
- PI. See *Package insert*.
- "Pink Book" (*Epidemiology and Prevention of Vaccine-Preventable Diseases*), iv, 59
- Plasma cells, 21-23, 22, 29
- Pneumococcal vaccines, 440-452, 444t-446t, 517t. See also
Streptococcus pneumoniae.
 contraindications/precautions, 447
 cost-benefit analysis, 441
 efficacy/immunogenicity, 442-443
 immunization program, 440-442
 minimum ages and intervals, 143t-144t
 PCV7 (pneumococcal conjugate vaccine, 7-valent), 442, 442t-446t
 contraindications/precautions, 447
 coverage, 61, 61, 63
 CPT and ICD-9-CM codes, 127t
 efficacy/immunogenicity, 442-443
 herd immunity and, 42, 43
 recommendations, 441, 447, 449t
 replacement with PCV13, 441-442, 449t
 safety, 443-447
 schedule, 253, 445t, 451t
 catch-up, children age 4 months-6 years, 246t-247t
 children, age 0-6 years, 243t
 shortages of, 84
- PCV13, 47, 442, 444t-446t
 CPT and ICD-9-CM codes, 127t
 efficacy/immunogenicity, 442-443
 recommendations, 447-448, 448t, 449t
 replacement of PCV7 with, 441-442, 449t
 safety, 447
 schedule, 253, 445t, 448t, 451t
- Pnu-Immune 23, 440
- PPSV23, 440-441, 442, 444t-446t
 CPT and ICD-9-CM codes, 127t
 efficacy/immunogenicity, 443, 450
 number of doses, reactogenicity and, 147
 recommendations, 183, 448-450
 safety, 447, 487
 schedule, 253, 445t, 451t
 administration errors, and remedies, 154t
 adults, by age, 249t
 adults, by medical condition/indication, 250t
 children, age 7-18 years, 245t
 recommendations, 447-450, 448t, 449t, 451t
 risk categories for IPD, 448-450
 safety, 95t, 443-447
 scenarios for/optimizing use of, 451t
 schedule, 445t, 449t, 451t
- Pneumonia, 439-440. See also *Pneumococcal vaccines; Streptococcus pneumoniae*
 from Hib, 287

Pneumovax 23 (PPSV23), 440-441, 442, 444t-446t. See also
 Pneumococcal vaccines, PPSV23.
 CPT and ICD-9-CM codes, 127t
 recommendations, 448-450
 safety, 447, 487
Pnu-Immune 23, 440
Policy. See *Vaccine policy.*
Polio, 391-396, 516t
 clinical features, 391
 eliminated from United States, 45, 392
 epidemiology and transmission, 391-392
 endemic regions of world, 185t-187t
 eradication initiative, 392-393
 immunization program, 392-393
 morbidity and mortality from, 46t
 pathogen, 391
 vaccines for, 393, 394t
 AIDS pandemic, concerns about, 234-235
 cancer and, concerns about, 234
 contraindications/precautions, 395
 inactivated (IPV), 15, 393, 394t
 combination vaccines, 253-254, 492t-496t
 contraindications/precautions, 395
 efficacy/immunogenicity, 393
 minimum ages and intervals for, 143t
 recommendations, 395
 safety, 94t, 395
 schedule, 253-254, 394t, 395
 catch-up, children 7-18 years, 248t
 catch-up, children age 4 months-6 years, 247t
 children, age 0-6 years, 243t
 children, age 7-18 years, 245t
 oral (OPV), 393
 efficacy/immunogenicity, 393
 reportable events, 94t, 191
 recommendations, 393, 395
 travel in endemic areas, 183
 safety, 191, 395
 SV40 contamination and, 70t, 234
Poliomyelitis. See *Polio.*
Polyclonal immune globulins, 16, 17
Polysaccharide vaccines, 16, 30
 hyporesponsiveness and, 23
 protein-polysaccharide vaccines, 16, 30, 31
 advantages of, 32t
 pure, 16, 23
Postherpetic neuralgia (PHN), 481, 484
Postpartum women, vaccinations for, 110, 148, 252, 271, 282
Power outages, 107t
PPSV23. See *Pneumococcal vaccines, PPSV23.*
Precautions. See *Contraindications and precautions.*
Pregnancy, 173-175
 FDA Pregnancy Categories, 173-174

Pregnancy (*continued*)
 natural immunization of fetus during, 16
 rubella in, effects on fetus, 367
 typhoid, transplacental transmission of, 454
 vaccination during, 173-175, 176t-177t, 250t-251t
 contraindications/precautions, 155, 255, 264t, 301, 329, 353, 371,
 395, 435, 467, 468, 477
 hepatitis B, 306-307
 influenza vaccines, 173, 176t, 354
 live vaccines, 174
 MMR, 373
 pertussis, 271
 pneumonia vaccination, 450
 Tdap and Td vaccines, 176t, 250t, 252, 282-283
 tetanus and diphtheria boosters, 174, 282-283
 VariZIG, 174-175
 yellow fever vaccination, 155, 478
Prescription Drug User Fee Act (PDUFA), 54
Preservative-free vaccines, 229. See also *specific vaccines.*
Preservatives, 224-229. See also *specific vaccines.*
Preterm and low birth weight infants, 175, 314, 421
Prevention of infection. See *Infection, preventing.*
Prenar (PCV7-CRM), 253, 442, 444t-446t. See also *Pneumococcal vaccines, PCV7.*
 CPT and ICD-9-CM codes, 127t
 replacement with Prenar 13 (PCV13), 441-442, 449t
 safety, 443-447
 schedule/recommendations, 441, 445t, 447, 449t, 451t
Prenar 13 (PCV13-CRM), 442, 444t-446t. See also *Pneumococcal vaccines, PCV13.*
 replacement of Prenar (PCV7) with, 441-442, 449t
 safety, 447
 schedule/recommendations, 445t, 447-448, 449t, 451t
Primary immunization, 27-28, 28
Primary vaccine failures, 29
Prions, 233-234
Probabilistic thinking, 192-195
Production problems, 82
Professional associations, 506
Proguanil therapy, 458
ProQuad (MMRV), 254, 498t-502t
 component vaccines/composition, 498t-499t
 CPT and ICD-9-CM codes, 127t
Protein-polysaccharide vaccines, 30, 31. See also *specific vaccines.*
 advantages of, 32t
Protest organizations (antivaccination), 201-204, 201t-203t
Pseudomembranes, 267
Public health, 44-47. See also *Concerns about vaccines, addressing.*
 immunization programs, goals of, 44-45
 impact of vaccines/vaccination programs, 45-47, 46t, 191
 risks of refusal of vaccination, 197-200
Public Health Service Act, 78
Public safety workers, vaccination of, 189t

- Purified subunits, 12t-13t, 15
- Purpura fulminans*, 379. See also *Neisseria meningitidis*.
- Questions about vaccines. See *Concerns about vaccines, addressing*.
- RAB-HDC. See *Imovax Rabies*.
- RAB-PCEC. See *RabAvert*.
- RabAvert (RAB-PCEC), 402t-404t
- CPT and ICD-9-CM codes, 127t
 - safety, 401
- Rabbit complement assay, 383
- Rabies, 397-411, 516t
- clinical features, 397-398
 - death from, 398
 - epidemiology and transmission, 398
 - immune globulin (HRIG), 399, 400, 410t
 - immunization program, 399
 - pathogen, 397
 - vaccines for, 400, 402t-404t. See also *Rabies immune globulin, human (HRIG)*.
 - administration errors, and remedies, 154t
 - for animal handlers, 102
 - contraindications/precautions, 401
 - CPT and ICD-9-CM codes, 127t
 - efficacy/immunogenicity, 400
 - postexposure prophylaxis, 399, 400, 408t-409t
 - regimens, 410t-411t
 - pre-exposure prophylaxis, 399, 406t-407t
 - recommendations, 401, 406t-409t
 - safety, 400-401
 - schedule/regimens, 403t, 410t-411t
 - vaccination of wildlife, 398
- Rabies immune globulin, human (HRIG), 399, 400, 410t
- contraindications/precautions, 401
 - efficacy/immunogenicity, 400
 - interval for receipt of live vaccines, 151t
 - regimens, 410t
 - safety, 401
- Ramsay Hunt syndrome, 482
- Reactions. See *Adverse events*.
- Reassortment, 14, 333
- Recall and tracking systems, 108-109
- Recombinant DNA technology, 16
- Recombinant subunit vaccines, 12t-13t
- Recombivax HB (HepB), 241-242, 308t-310t
- CPT and ICD-9-CM codes, 125t
 - dosing, 309t, 312
 - efficacy/immunogenicity, 311
- Recommendations, 139-158. See also *specific vaccines*.
- ACIP, 58-59
 - agencies involved with, 56-60, 57
 - contraindications and precautions, 155-156
 - general rules for vaccination, 139-155
- Recommendations (*continued*)
- permissive statements, 59
 - risk-based immunization, 59
 - routine immunization, 59
 - schedules for routine vaccinations, 241-256
 - vaccine handling, storage, and transport, 105-108
 - vs package insert information, 55, 156
- Reconstitution of vaccine, 113
- Recurrent respiratory papillomatosis, 320
- "Red Book" (*Report of the Committee on Infectious Diseases*), iv, 59
- Refrigerators and freezers, 105-106, 107t
- Refugees, international, 178-179
- Refusal of vaccination, 197-200
- impact of, examples, 204-208, 206t-207t
 - Refusal to Vaccinate* form, 198-199
- Registries. See *Immunization Information Systems (IISs)*.
- Regulations. See *Standards, principles, and regulations*.
- Religious exemptions, 103
- Reminder, recall, and tracking systems, 108-109
- Report of the Committee on Infectious Diseases*. See "Red Book".
- Reportable Events Table, 94t-95t
- Respiratory syncytial virus (RSV), monoclonal antibody to (RSVmAB), 17, 131t, 150t
- Respiratory syncytial virus (RSV) immune globulins, 129t
- REST (Rotavirus Efficacy and Safety Trial), 416, 417
- Reverse genetics, 338
- Reye syndrome, 353, 354, 462, 467
- Rhesus rotavirus vaccine, tetraivalent. See *RRV-TV*.
- RhoGAM (IM), 151t
- Risks
- of daily activities, 191-192
 - of delayed vaccination, 215
 - known vs unknown, 193
 - perceived, 193
- Risks and benefits of vaccines
- communicating about, 191-197, 208-236
 - in impaired immunity, 159
 - public health risk of vaccine refusals, 197-200
 - safety and utility of vaccines, 191-197
 - thought processes about, 192-195
 - weighing, 155-156, 173, 191-192, 210
- The River: A Journey to the Source of HIV and AIDS* (Hooper), 234
- Rose spots, 453
- Rotarix (rotavirus, RV1), 242, 416, 418t-420t
- composition, 416, 418t
 - CPT and ICD-9-CM codes, 127t
 - efficacy/immunogenicity, 417
 - safety, 417-421
- RotaShield (RRV-TV), 69-72, 415
- RotaTeq (rotavirus, RV5), 242, 415, 418t-420t. See also *Rotavirus, vaccines for*.
- composition, 416, 418t
 - cost of development of, 49

- RotaTeq (rotavirus, RV5) (*continued*)
 CPT and ICD-9-CM codes, 127t
 efficacy/immunogenicity, 416
 safety, 55-56, 417
- Rotavirus, 413-423, 516t
 clinical features, 413-414
 epidemics, 414
 epidemiology and transmission, 414
 immunization program, 415-416
 office visits, hospitalizations, and deaths, annual, 414
 pathogen, 413
 Rotavirus Efficacy and Safety Trial (REST), 416, 417
 vaccines for, 14, 416, 418t-420t
 composition, 416, 418t
 contraindications/precautions, 421
 cost-benefit analysis, 415
 CPT and ICD-9-CM codes, 127t, 130t-131t
 efficacy/immunogenicity, 416-417
 minimum ages and intervals, 144t
 monitoring, 64-65
 recommendations, 421-422
 RRV-TV, 415
 RV-1, 416, 418t-420t
 RV-5, 415, 418t-420t
 safety, 95t, 417-421
 Kawasaki disease concerns, 236
 schedule, 242, 419t
 catch-up, children, 4 months-6 years, 246t
 children, age 0-6 years, 243t
- Routes of inoculation, 15
- RRV-TV (rhesus rotavirus vaccine; RotaShield), 69-72, 415
- RSV. See *Respiratory syncytial virus (RSV)*.
- Rubella, 365-377, 516t. See also *Measles, Mumps, Rubella*.
 clinical features, 367
 criteria for immunity, 373, 374t-375t
 eliminated from United States, 45
 epidemiology and transmission, 368-369
 immunization program, 369
 morbidity and mortality from, 46t
 pathogen, 365
 in pregnant women, 367
 vaccines for, 370, 372t-373t
 contraindications/precautions, 371-373
 CPT and ICD-9-CM codes, 127t, 131t
 efficacy/immunogenicity, 370-371
 recommendations, 373-376
 safety, 94t, 371-373
- Rubeola. See *Measles*.
- Rules for vaccination. See *Recommendations*.
- Sabin, Albert, 11
- Sabin Vaccine Institute (SVI), 507
- Safety net. See *Vaccine Safety Net*.
- Safety of vaccines. See also *Vaccine Safety Net; And specific vaccines*.
 communicating about, 191-197, 208-236
 definitions of, 191-192
 ISRC findings, 70t-71t
 specific concerns, 208-236
 Salicylate use. See *Aspirin use*.
- Salk, Jonas, 15
- Salmonella enterica*. See *Salmonella typhi*.
- Salmonella typhi*, 14, 453. See also *Typhoid fever*.
- Schedules for immunizations, 241-256. See also *specific vaccines*.
 adults, by age group, 249t
 adults, by medical condition, 250t-251t
 catch-up schedule, children age 4 months-6 years, 246t-247t
 catch-up schedule, children age 7-18 years, 248t
 children, age 0-6 years, 243t-244t
 children, age 7-18 years, 245t
 modified/alternative, 199, 214-215
 specific vaccines,, s for, 241-256
- SCHIP (State Children's Health Insurance Program), 78
- School mandates, 102-103
- School surveys, 62-63
- Screening for contraindications/precautions/other problems,
 113, 114t-115t
- Section 317 Funds, 73, 78, 111
- Serial passage, 11-14
- Seroconversion, testing for, 149
- Serology, 149
- Serotype replacement, 43
- Sewage workers, 189t
- Sharps use and precautions, 100-101
- Shingles. See *Zoster (herpes zoster; shingles)*.
- Shortages of vaccines, 79-83, 84
- Sickle cell disease, 164
 pneumonia and, 440
 pneumonia vaccination, 451t
- Side effects. See *Adverse events*.
- SIDS. See *Sudden infant death syndrome*.
- Simian immunodeficiency virus (SIV), 234-235
- Simian virus 40 (SV40), 70t, 234
- Smallpox, 425-438, 517t
 bioterrorism potential of, 44, 426
 clinical features, 425-426
 diagnosis of, 426, 428t-429t
 eradication of, 44-45, 426
 immunization program, 427-430
 morbidity and mortality from, 46t
 pathogen, 425
 Smallpox Health Care Teams, 437
 Smallpox Response Teams, 430
 vaccines for, 430-433, 431t
 ACAM2000, 431t, 433-434
 amount available, 430
 contraindications/precautions, 435-436

- Smallpox, vaccines for (*continued*)
 - CPT and ICD-9-CM codes, 127t
 - Dryvax, 430, 433
 - vs ACAM2000, 433-434
 - efficacy/immunogenicity, 433-434
 - handling and administration, 116, 430-433
 - injury compensation program, 436
 - postevent vaccination, 427, 436-437
 - pre-event vaccination, 427, 436
 - recommendations, 427-430, 436-438
 - ring vaccination (surveillance and containment), 427
 - safety, 434-436
 - schedule, 139, 431t
 - vaccinia immune globulin (VIG), 436
 - variola major and minor, 425-426
 - variola virus, 425-426
 - vs chickenpox, 428t-429t
- Special circumstances, 159-190
 - health care personnel, 179-181
 - impaired immunity, 159-173
 - general considerations, 159-162
 - hematopoietic stem cell transplantation and leukemia, 169, 170t-172t
 - HIV infection, 167-169
 - medication-induced immunosuppression, 165-167
 - specific states other than HIV infection, 162-165
 - international adoptees, refugees, and immigrants, 178-179
 - other special circumstances, 184, 188t-189t
 - pregnancy and breast-feeding, 173-175, 176t-177t
 - preterm and low birth weight infants, 175
 - travel, 182-184, 185t-187t
- Spelunkers, 189t
- Split doses, 141
- Squamous cell carcinoma of the cervix, 319
- Standards, principles, and regulations, 87-104
 - Bloodborne Pathogens Standard, 97-102
 - CBER, for vaccine development, 49-51
 - federal requirements regarding vaccination, 98t-99t
 - Healthy People 2010 and 2020*, 87
 - immunization practices, standards, 88-91
 - adult, 91, 92t
 - pediatric, 88-91
 - National Childhood Vaccine Injury Act, 91-97
 - Occupational Safety and Health Administration, 97-102
 - school mandates and state legislation, 102-103
- Standing orders, 110-111
 - for birth dose, HepB vaccination, 312
 - for emergencies, 119
- Staphylococcus aureus*, secondary infections in varicella, 462
- State and local funds for vaccination, 73, 78
- State Children's Health Insurance Program (SCHIP), 78
- State health department immunization program web sites, 508
- State legislation on vaccinations, 102-103
- Status quo, maintaining, 194
- Steroids, impaired immunity and, 166-167
- Storage of vaccines, 105-108. See also *specific vaccines*.
 - during emergencies, 107t
- Streptococcus pneumoniae*, 439-452, 517t
 - clinical features, 439-440
 - invasive pneumococcal disease (IPD), 439, 440
 - epidemiology and transmission, 440
 - immunization program, 440-442
 - morbidity and mortality from, 46t, 440
 - newborn protection against, 16
 - pathogen, 439
 - replacement disease, 441
 - risk categories for IPD, 448-450
 - vaccines for, 442, 444t-446t. See also *Pneumococcal vaccines*.
 - cost-benefit analysis, 441
 - efficacy/immunogenicity, 442-443
 - recommendations, 447-450
 - safety, 443-447
 - scenarios for/optimizing use of, 451t
 - schedule, 447-448, 448t, 449t
- Students. See *College students*.
- Subcutaneous (SC) administration of vaccines, 116, 118, 120t-121t
- Subunits
 - engineered, 12t-13t, 16
 - purified, 12t-13t, 15
 - recombinant, 12t-13t
- Sudden infant death syndrome (SIDS), vaccinations and, 71t, 235
- Supply of vaccines, 79-83, 84
- Surrogates of protection, 36-39, 38t
- Surveillance, 64-72
- SV40 contamination of polio vaccine, 70t, 234
- Swine flu vaccine, 68, 71t, 231
- Synagis (RSV immune globulin, monoclonal, IM), 129t
- Syncope, 119
- T-cell dependent response, 30
- T-cell independent antigens and responses, 23, 30
- T-cell receptor (TCR), 24, 25, 30
- T cells, cytotoxic. See *Cytotoxic T cells*.
- T lymphocytes, helper (Th-cells), 24-26, 25, 33
- Task Force on Safer Childhood Vaccines (TFSCV), 68-69
- TB. See *Tuberculosis*.
- Tc cells. See *Cytotoxic T cells*.
- Td (tetanus, diphtheria) vaccine, 276t-278t
 - contraindications/precautions, 280-281
 - CPT and ICD-9-CM codes, 127t
 - indications, 277t
 - minimum ages and intervals for, 144t
 - recommendations
 - boosters, 252
 - pregnancy, 176t
 - travel, 183-184

- Td (tetanus, diphtheria) vaccine (*continued*)
 schedule, 252, 277t
 adults, by age, 249t
 adults, by medical condition/indication, 250t
 catch-up, children age 7-18 years, 248t
 shortages of, 84
- Tdap vaccine, 39, 252, 272t-275t. See also *Adacel*; *Boostrix*; *DTaP*.
 adolescent immunization, 271
 contraindications/precautions, 279-280
 CPT and ICD-9-CM codes, 128t
 efficacy/immunogenicity, 279
 health care workers, vaccination of, 102, 181
 intervals for vaccination, 144t
 minimum ages and intervals, 144t
 in pregnancy, 176t
 recommendations, 252, 281-283
 safety, 279-281
 schedule, 252, 274t
 administration errors, and remedies, 154t
 adults, by age, 249t
 adults, by medical condition/indication, 250t
 catch-up, children, age 7-18 years, 248t
 children, age 7-18 years, 245t
- Terrorism. See *Bioterrorism*.
- Tetanospasmin, 267
- Tetanus, 267-286, 516t
 clinical features, 268
 epidemiology and transmission, 269
 immunization program, 270
 morbidity and mortality from, 46t
 pathogen, 267
 toxin, 267, 272t
 toxoid. See *Tetanus toxoid (TT)*.
 vaccination for travel, 183-184
 vaccines for, 252, 272t-278t, 516t. See also *DT*; *Tetanus toxoid (TT)*.
 adult. See *Tdap vaccine*.
 children/infants. See *DTaP vaccine*.
 combination vaccines, 492t-496t
 contraindications/precautions, 279-281
 CPT and ICD-9-CM codes, 127t-128t
 efficacy/immunogenicity, 271-279
 indications, 273t, 277t
 minimum ages and intervals, 144t
 recommendations
 general use, 281-283
 wound management, 284t-285t
 safety, 94t, 279-281
 schedule, 274t, 277t
- Tetanus immune globulin (TIG)
 for at-risk HIV-infected children, 162
 CPT and ICD-9-CM codes, 129t
 interval for receipt of live vaccines, 151t
- Tetanus Toxoid Adsorbed (TT), 276t-278t
 CPT and ICD-9-CM codes, 124t, 127t
- Tetanus toxoid (TT), 276t-278t
 contraindications/precautions, 147, 280-281
 CPT and ICD-9-CM codes, 124t, 127t-128t
 recommendations, 284t-285t
- Th-cells (helper T lymphocytes), 24-26, 25, 33, 33
 Th1-cells, 26, 33, 33
- Thimerosal, 224-229. See also *specific vaccines*.
 autism and, 224-229, 227, 228
 in MMR, concerns about, 208
 safety findings, 70t
- Thrombocytopenia/thrombocytopenic purpura, 371
- TIG. See *Tetanus immune globulin*.
- Timeliness, 60-64
- TIV, 346t
- TLRs. See *Toll-like receptors (TLRs)*.
- Toll-like receptors (TLRs), 24
- Topical anesthetics, 117
- Toxins
 concerns about, 213
 diphtheria, tetanus, and pertussis, 267, 272t
 enterotoxin, rotavirus, 413
 neutralization of, 21
 typhoid, 453
- Toxoid vaccines, 12t-13t, 15, 276t-278t
- Tracheal cytotoxin, 267
- Tracking systems, 108-109
- Transplantation, impaired immunity and, 165-166, 169, 170t-172t
- Transportation of vaccines, 106-108
- Travel, vaccination for, 182-184, 185t-187t, 297, 302, 355, 363, 388, 459, 477
- Trials, clinical, 51-54, 51
- TriHIBit (DTaP/Hib), 242, 252, 492t-496t
 component vaccines/composition, 492t-493t
 CPT and ICD-9-CM codes, 124t
- Tripedia (DTaP), 272t-275t
 CPT and ICD-9-CM codes, 124t
 efficacy, 271-279
- TT. See *Tetanus toxoid (TT)*.
- Tuberculosis (TB), untreated, as precaution for vaccination, 468, 484
- TViPSV. See *Typhim Vi*.
- Twinrix (HepA-HepB), 242, 255, 498t-502t
 component vaccines/composition, 498t
 CPT and ICD-9-CM codes, 125t
- Typhim Vi (TViPSV, pure polysaccharide vaccine), 445, 456t-457t
 CPT and ICD-9-CM codes, 128t
 efficacy/immunogenicity, 455
 safety, 458
- Typhoid fever, 453-460, 517t
 clinical features, 453-454
 epidemiology and transmission, 454
 endemic regions of world, 185t-187t

Typhoid fever (*continued*)

- immunization program, 454-455
- multidrug-resistant infection, 454-455
- pathogen, 453
- vaccines for, 445, 456t-457t
 - contraindications/precautions, 458
 - CPT and ICD-9-CM codes, 128t
 - efficacy/immunogenicity, 455-458
 - engineered attenuation of, 14-15
 - interval for other live vaccine, 139-140
 - recommendations, 459
 - safety, 458

Universal precautions, 100-101

US Agency for International Development (USAID), 506

US Food and Drug Administration. See *Food and Drug Administration (FDA)*.

Utility of vaccines, 192

Vaccinate Your Baby, 507

Vaccination. See also *Immunization*; *Vaccinology*.

- basic concepts, 11-48
- costs-benefit analysis of, 47
- goals of, 44-45
- public health impact, 45-47, 46t, 191
- reduction in morbidity/mortality from, 46t

Vaccination programs, 44-47, 46t. See also *Immunization programs*.

Vaccination refusal. See *Refusal of vaccination*.

Vaccine Adverse Event Reporting System (VAERS), 66-67, 90, 96, 98t, 505

Vaccine and Treatment Evaluation Unit (VTEU), 57

Vaccine court, 225-226

Vaccine development and licensure, 49-56. See also *Vaccine infrastructure*.

- agencies involved with, 56-60, 57
- Biologics License Application (BLA), 54
- clinical trials, 51-54
- financial risk in, 49
- package insert (PI), 54-56
- process of, 50

Vaccine immunology, 17-35. See also *Immune response*.

Vaccine Information Statements (VISs), 89, 97, 98t

Vaccine infrastructure in the United States, 49-86

- financing, 72-79
- monitoring delivery, 60-64
- monitoring effectiveness, 64-65
- policy and recommendations, 56-60
- supply, 79-83, 84
- vaccine development and licensure, 49-56
- Vaccine Safety Net, 65-72

Vaccine Injury Compensation Program (VICP), 92-96, 505

- covered vaccines, 99t
- important point, 96
- Reportable Events Table, 94t-95t

Vaccine policy and recommendations, 56-60. See also

Recommendations.

agencies involved with, 56, 57

Vaccine practice, 105-138

- administration, 113-117
- coding, billing, and vaccine costs, 122-136
- delivery, improving, 108-113
- emergencies, 117-122
- handling, storage, and transport, 105-108
- screening, 113, 114t-115t

Vaccine-preventable diseases, 64-65

morbidity and mortality from, 45, 46t

Vaccine protest organizations, 201-204, 201t-203t

Vaccine recommendations. See *Recommendations*.

Vaccine registries. See *Immunization Information Systems (IISs)*.

Vaccine Research Center (VRC), 505

Vaccine Safety DataLink (VSD), 67, 220

Vaccine Safety Net, 65-72, 65t

- safety findings, ISRC, 70t-71t

Vaccine(s). See also *Immunization*; *specific vaccines*.

- classification, 12t-13t
- communicating about, 191-240
- concerns about, addressing, 191-240
- costs/cost-benefit analyses. See *Costs*.
- delivery. See *Delivery of vaccines*.
- development. See *Vaccine development and licensure*.
- equivalence of different manufacturers, 147
- funding for. See *Financing*.
- inactivated, 15, 18t-20t
- licensure. See *Vaccine development and licensure*.
- live, 11-16, 12t-13t
 - vs inactivated, 18t-20t
- necessity for, 208-209
- recommendations regarding. See *Recommendations*.
- schedules for. See *Schedules for immunizations*.
- specificity of, 28-29
- supply/shortages, 79-83, 84
- types of, 12t-13t

Vaccines and Related Biological Products Advisory Committee (VRBPAC), 54, 505

Vaccines for Children (VFC) Program, 56, 74-78, 505

- actions required under, 75t
- common questions about, 76t-77t
- potential expansion of, 80t

Vaccinia immune globulin (VIG), 436

Vaccinia virus. See also *Smallpox*.

Vaccinology, 11-48. See also *Immunization*.

- basic vaccine immunology, 17-35
- correlates of protection, 36-39, 38t
- genetics of vaccine responses/adverse events, 43
- herd immunity, 39-43
- immunization, 11-16
- public health and vaccines, 44-47, 46t, 191

- Vaccinomics, 43
- VAERS. See *Vaccine Adverse Event Reporting System*.
- Vaginal intraepithelial neoplasia (VaIN), 320
- Vapocoolant sprays, 117
- Vaqa (HepA), 255, 298t-300t
 CPT and ICD-9-CM codes, 124t
 efficacy/immunogenicity, 301
- Varicella, 461-471, 517t
 breakthrough/vaccine-modified, 461-462
 chickenpox and, 461
 clinical features, 461-462
 congenital, 462
 criteria for immunity, 469t
 epidemiology and transmission, 462-463
 herpes zoster (shingles) and, 462. See also *Zoster*.
 immunization program, 463-464
 latent infection, 461
 reactivation of, 462, 481
 morbidity and mortality from, 46t
 passive immunoprophylaxis (VariZIG), 469-470
 pathogen, 461
 progressive, 462
 vaccines for, 464, 466t-467t
 contraindications/precautions, 160, 467-468
 cost-benefit of vaccination, 464
 coverage, 61
 CPT and ICD-9-CM codes, 128t, 131t
 efficacy/immunogenicity, 464-465
 interval for receipt of antibody-containing products, 150t-151t
 minimum ages and intervals, 144t
 recommendations, 468-470
 safety, 95t, 465-468
 schedule, 47, 254, 466t
 administration errors, and remedies, 154t
 adults, by age, 249t
 adults, by medical condition/indication, 250t
 catch-up, children age 4 months-6 years, 247t
 catch-up, children age 7-18 years, 248t
 children, age 0-6 years, 243t
 children, age 7-18 years, 245t
 interval for smallpox and, 139
 shortages of, 84
 vs zoster (shingles) vaccine, 35, 147
 vs smallpox, 428t-429t
 waning immunity and, 462
- Varicella-zoster immune globulin (VariZIG), 469-470
 adverse reactions, 470
 CPT and ICD-9-CM codes, 129t, 131t
 interval for receipt of live vaccines, 151t
 investigational new drug protocol, obtaining under, 470
 post-exposure, 162, 469-470
 recommendations, 469-470
 safety, 470
- Varicella-zoster virus (VZV), 461. See also *Varicella*.
 reactivation of latent, 462, 481. See also *Zoster (herpes zoster; shingles)*.
- Variola, 425-426. See also *Smallpox*.
- Varivax (varicella vaccine), 254, 466t-467t. See also *Varicella*,
 vaccines for:
 CPT and ICD-9-CM codes, 128t
 efficacy/immunogenicity, 464-465
 recommendations, 468-470
 safety, 465-468
- VariZIG, 174-175, 469-470
- VFC. See *Vaccines for Children (VFC) Program*.
- VICP. See *Vaccine Injury Compensation Program*.
- Viscerotropic disease, vaccine-associated, 476
- VISs. See *Vaccine Information Statements*.
- Vivotif (Ty21a, live-attenuated typhoid vaccine), 445-448, 456t-457t
 CPT and ICD-9-CM codes, 128t
- Voices for Vaccines, 507
- Vomito negro, 473
- VRBPAC. See *Vaccines and Related Biological Products Advisory Committee*.
- VSD. See *Vaccine Safety DataLink*.
- VTEU. See *Vaccine and Treatment Evaluation Unit*.
- Vulvar intraepithelial neoplasia (VIN), 320
- Waning immunity, 209, 271, 462
- Warnings, 156. See also *Contraindications and precautions*.
- Whole agent vaccines, 12t-13t, 15
- Whooping cough, 268-269. See also *Pertussis*.
- Woolsorter's disease, 257
- World Health Organization (WHO), 49, 506
- Wound management, tetanus prophylaxis for, 284t-285t
- Wounds, contamination of. See *Tetanus*.
- X-linked agammaglobulinemia, 163
- Yellow fever, 473-479, 517t
 certificates of vaccination, 478
 clinical features, 473
 epidemiology and transmission, 473-474
 endemic regions of world, 185t-187t
 immunization program, 474
 pathogen, 473
 vaccine for, 11, 474, 475t
 adverse events, serious, 476
 contraindications/precautions, 162, 477
 CPT and ICD-9-CM codes, 128t
 efficacy/immunogenicity, 476
 intervals for vaccination, 139
 polyclonal immune globulin and, 17
 recommendations, 485-487
 mandatory for some travel, 184
 safety, 476-477
 schedule, 475t

Yellow fever virus (YFV), 473
YF-Vax (yellow fever vaccine), 474, 475t. See also *Yellow fever*.
 CPT and ICD-9-CM codes, 128t
Youth Risk Behavior Study, 321

Zostavax (ZOS, zoster vaccine), 474, 476t-477t
 CPT and ICD-9-CM codes, 128t
 recommendations, 486-487

Zoster (herpes zoster; shingles), 461, 481-488, 517t. See also *Varicella*.
 clinical features, 481-482
 epidemiology and transmission, 482-483
 immunization program, 483-484
 incidence, 483
 pathogen, 481
 postherpetic neuralgia (PHN) and, 481, 484
 vaccine for, 474, 476t-477t
 contraindications/precautions, 484, 487
 cost-benefit of vaccination, 483-484
 CPT and ICD-9-CM codes, 128t
 efficacy/immunogenicity, 484-485
 minimum ages and intervals, 144t
 recommendations, 255, 485-487
 safety, 484
 schedule, 255, 486t, 487
 administration errors, and remedies, 154t
 adults, by age, 249t
 adults, by medical condition/indication, 250t
 vs varicella vaccine, 35, 147